SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. - Wikidata - awgldk - TriplyDB

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

http://www.wikidata.org/entity/Q44280921

about

The role of FLT3 in haematopoietic malignancies Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives Chloroquine and hydroxychloroquine for cancer therapy Individualising treatment choices in a crowded treatment algorithm Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.Sunitinib in the treatment of metastatic renal cell carcinoma Patient-derived tumour xenografts for breast cancer drug discovery Sunitinib in solid tumors Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations Mutant FLT3 signaling contributes to a block in myeloid differentiation Human iPSC-derived endothelial cell sprouting assay in synthetic hydrogel arrays The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment (3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies An ex vivo model for anti-angiogenic drug testing on intact microvascular networks Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia Lymphangiogenesis is required for pancreatic islet inflammation and diabetes Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer Systematic identification of genomic markers of drug sensitivity in cancer cells Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.Sunitinib malate for the treatment of solid tumours: a review of current clinical data.Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth.Systemic therapy options for unresectable and metastatic chordomas.Precancerous stem cells can serve as tumor vasculogenic progenitors.Phase II study of sunitinib as second-line treatment for advanced gastric cancer.Sunitinib in metastatic renal cell carcinoma patients with brain metastases.Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors.Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy.

P2860

Q24319174-48451AA9-F258-44E4-9360-B697FE7350C8 Q24617091-CDECAD8A-1565-4AF1-A0F9-E7DE4C1CE4DE Q26826817-E589FAE7-62EC-436D-804B-D5D8E77E54C5 Q26827797-6B3C7AFF-9931-4E14-8E54-47E86BBAF26D Q27023669-BF438988-E31F-49DD-BA8C-7B8CE204C708 Q27674674-3305680C-BA85-414A-BF35-7A09458620E3 Q27851455-E483A84D-5CCC-4106-8B07-50ADA7F4F560 Q27851744-94E37338-0C0F-47EF-BD2F-E3FE14BE5985 Q27852520-ABD8B274-7E61-440F-AFBE-5F5CB0DCDCDB Q28072057-C3BCF210-126B-436F-B55C-FB143B2D9635 Q28080046-88BEB0B5-3730-4F48-9161-C1678DEACBAA Q28245467-5F7A8822-4D32-492A-9ADE-018793868DDF Q28247449-9ED0EAAC-14A1-42D1-87C3-79307A4C9C0F Q28279890-31FB6EDB-BF45-4E8D-9ADE-95216A04B98B Q28397986-A65E61F8-5EC3-4EF8-9499-3647CB6B87E7 Q28474942-6D0DBC15-1218-4D8F-BCA1-126E75AD6769 Q28488869-311314C4-284A-4795-BA94-FBB55CF575D8 Q28543862-D17FD878-0FDC-4C91-8775-32A024234B9E Q28550556-A1F49419-6561-473B-A643-FD70DFB6D60F Q28608331-7E36F1B2-203E-4000-8512-BACE58110F9E Q28742322-84620861-38C6-4FF0-A6C3-388E5E7A7ECB Q29012696-0D231CA3-0E5B-4959-B86E-E8398753A1E1 Q29147555-DB8F0EC7-B58D-4695-9AE6-8103E39C9078 Q29547695-E28FABE3-A457-4595-8908-FCA4AD8DACD1 Q30313895-5B4424D1-0C5C-4DDB-9E20-0284C118B494 Q30422736-91D4A643-9754-451D-9BFA-33A59EB90976 Q31037756-629A624C-42E9-4A94-AF6D-5ACE0F1880B8 Q33216322-4EC9AC0B-93AE-414F-BCFD-6190E32ACDE2 Q33274146-25A2CC05-56CA-45F4-B20A-52F5FB42553D Q33320547-6839D59E-E36F-4603-9354-E09A6D6E6355 Q33389519-DDD8FAA3-8550-4E34-8BD3-6BA3B1976467 Q33391978-832A6313-A296-43C2-85E6-01CD9898EF63 Q33395853-A40B0E78-05DC-4FAB-84EB-A40B263F8C34 Q33397590-D649FCF7-EDA2-4251-A33E-A2A777ABD153 Q33400952-B370D38D-3E75-4997-9054-7222107DAA53 Q33401396-D9F0DDE3-CFE5-4A0C-AB37-6DE4111CD967 Q33406542-80C6E85C-AD65-4819-ADBD-0A511B5F841B Q33407676-EB118EF3-F1FE-43DE-B68D-E87D032A7644 Q33409913-D5AA9405-023B-4B74-9131-9757C523BD42 Q33413566-3A2540B8-47FF-4BA7-B729-9649FBEC5AC3

P2860

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

http://www.wikidata.org/entity/Q44280921

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.

@en

SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.

@nl

type

label

SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.

@en

SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.

@nl

prefLabel

SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.

@en

SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.

@nl

P1433

Q44280921-2CFF730E-6EE3-4052-B3FE-65FEFE2FF113

P1476

Q44280921-578F3D5A-3FCE-4C5F-862A-705DDA97C84E

P2093

Q44280921-001B7CC5-1419-4ED8-B9EF-E6AEC16C23BA

Q44280921-06758E9B-251A-4C17-B7E5-CCD1DB90C846

Q44280921-12952E0A-E67F-4099-AD21-4C38FFCE9A22

Q44280921-1D59B571-6A64-40AA-9527-4AC3DDD00E35

Q44280921-1EB11C49-4B64-42BB-8214-04454D46DA1A

Q44280921-3334B174-DBA8-4092-A5D6-786A15437746

Q44280921-62149EB6-556C-444E-A8EB-B1CFCB5DBF87

Q44280921-7D4E7D60-52A7-49E8-9897-A919445DE722

Q44280921-989954CE-5250-44B5-A4B8-3CC41C067FC6

Q44280921-A960C503-DA38-4BA0-A796-5C052E3C8633

P304

Q44280921-714661D5-CBEA-4837-809F-87B9F455F71D

P31

Q44280921-D2B9169E-3E52-4F57-A340-C834B4FFB159

P356

Q44280921-D5140472-FBA4-43E9-81CB-7F47D854EC23

P407

Q44280921-31AAE349-871E-432F-A237-C24049E5E0E2

P433

Q44280921-21FF278E-DEFB-4C37-8519-075D61997DEF

P478

Q44280921-871F1503-7FFE-4B6E-99A1-D38AB8DFA7BA

P50

Q44280921-022341D4-6121-47D1-A714-121B96850233

P577

Q44280921-2B072BCD-CA51-4349-9478-8DD1E0BB90E3

P5875

Q44280921-58F0002A-566F-4969-B8AD-1901B2632395

P698

Q44280921-7CF69DAD-B95B-484A-B1CC-09418ACAFE29

P356

BLOOD-2002-07-2307

P1433

P1476

SU11248 is a novel FLT3 tyrosi ...... activity in vitro and in vivo.

@en

P2093

Ajia Town

http://www.w3.org/2001/XMLSchema#string

Anne-Marie O'Farrell

http://www.w3.org/2001/XMLSchema#string

Beverly D Smolich

http://www.w3.org/2001/XMLSchema#string

Helene A Yuen

http://www.w3.org/2001/XMLSchema#string

Julie M Cherrington

http://www.w3.org/2001/XMLSchema#string

Kevin W H Yee

http://www.w3.org/2001/XMLSchema#string

Lesley J Murray

http://www.w3.org/2001/XMLSchema#string

Leslie B Lee

http://www.w3.org/2001/XMLSchema#string

Lily M Wong

http://www.w3.org/2001/XMLSchema#string

Sharianne G Louie

http://www.w3.org/2001/XMLSchema#string

P304

3597-3605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2002-07-2307

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Michael C. Heinrich

P577

2003-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10946867

http://www.w3.org/2001/XMLSchema#string

P698

12531805

http://www.w3.org/2001/XMLSchema#string